Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase...( TSX...),Health

TSX: BMR

TORONTO, Feb. 26 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Phase II data on the Company's Neuradiab product candidate as a treatment for newly diagnosed glioblastoma multiforme (GBM) were published in the journal, Neuro-Oncology. (http://neuro-oncology.dukejournals.org/cgi/rapidpdf/15228517-2007-053v1) This report summarizes the most recent clinical results utilizing patient-specific dosing of Neuradiab (I-131 mAb81c6) as an adjunctive therapy to oral chemotherapy, surgery and external beam radiation in patients with newly diagnosed GBM.

The study, conducted at Duke University Medical Center evaluating the efficacy and toxicity of Neuradiab as an adjunct to standard of care therapy in a 21 patient trial, demonstrated a 42 percent increase in overall survival compared to a historical control of the current standard of care. The article titled, "A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost", written by David A. Reardon and Michael R. Zalutsky as lead authors, will be published in the April 2008 edition of Neuro-Oncology.

"This article represents a detailed review of the results from the patient-specific dosing protocol utilized in the Neuradiab Phase II trial. The study forms the basis for the design of our multi-center Phase III trial. We are pleased to have the results published and look forward to working with Dr. David Reardon as the principal investigator and our extensive base of investigators and thought leaders as we approach the start of our multi-center trial," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "The article outlines the potential benefit of patient-specific dosing wi
'/>"/>